XERS vs. CTMX

Last updated Jun 24, 2026

XERS (Xeris Biopharma Holdings, Inc.) and CTMX (CytomX Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, XERS returned 10.76%/yr vs -14.01%/yr for CTMX. At a 0.29 correlation, their price movements are largely independent.

Performance

XERS vs. CTMX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Xeris Biopharma Holdings, Inc. (XERS) and CytomX Therapeutics, Inc. (CTMX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, XERS achieves a -8.28% return, which is significantly higher than CTMX's -26.06% return.

XERS

• 1D: 4.35%
• 1M: 16.32%
• YTD: -8.28%
• 6M: -1.10%
• 1Y: 55.17%
• 3Y*: 34.94%
• 5Y*: 10.76%
• 10Y*: —

CTMX

• 1D: 3.62%
• 1M: -16.22%
• YTD: -26.06%
• 6M: -25.00%
• 1Y: 45.83%
• 3Y*: 26.94%
• 5Y*: -14.01%
• 10Y*: -10.76%

*Multi-year figures are annualized to reflect compound growth (CAGR)

XERS vs. CTMX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
XERS Xeris Biopharma Holdings, Inc.	-8.28%	131.56%	44.26%	76.69%	-54.61%	-40.45%	-30.21%	-58.53%	7.94%
CTMX CytomX Therapeutics, Inc.	-26.06%	313.59%	-33.55%	-3.13%	-63.05%	-33.89%	-21.18%	-44.97%	-41.20%

Correlation

The correlation between XERS and CTMX is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.23
Correlation (3Y) Calculated over the trailing 3-year period	0.31
Correlation (5Y) Calculated over the trailing 5-year period	0.32
Correlation (All Time) Calculated using the full available price history since Jun 21, 2018	0.29

Fundamentals

Market Cap XERS : $1.28B CTMX : $558.41M
EPS XERS : $0.07 CTMX : -$0.37
PS Ratio XERS : 3.95 CTMX : 14.21
PB Ratio XERS : 98.30 CTMX : 1.75
Total Revenue (TTM) XERS : $314.85M CTMX : $35.54M
Gross Profit (TTM) XERS : $187.04M CTMX : $24.77M
EBITDA (TTM) XERS : $41.72M CTMX : -$62.07M

Return for Risk

XERS vs. CTMX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XERS

XERS Risk / Return Rank: 69
XERS Sharpe Ratio Rank: 73
XERS Sortino Ratio Rank: 70
XERS Omega Ratio Rank: 72
XERS Calmar Ratio Rank: 66
XERS Martin Ratio Rank: 62

CTMX

CTMX Risk / Return Rank: 62
CTMX Sharpe Ratio Rank: 59
CTMX Sortino Ratio Rank: 66
CTMX Omega Ratio Rank: 65
CTMX Calmar Ratio Rank: 60
CTMX Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XERS vs. CTMX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and CytomX Therapeutics, Inc. (CTMX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	XERS	CTMX	Difference
Sharpe ratio: Return per unit of total volatility	1.00	0.49	+0.50
Sortino ratio: Return per unit of downside risk	1.66	1.46	+0.20
Omega ratio: Gain probability vs. loss probability	1.23	1.19	+0.04
Calmar ratio: Return relative to maximum drawdown	1.19	0.81	+0.38
Martin ratio: Return relative to average drawdown	2.08	1.89	+0.19

XERS vs. CTMX - Sharpe Ratio Comparison

The current XERS Sharpe Ratio is 1.00, which is higher than the CTMX Sharpe Ratio of 0.49. The chart below compares the historical Sharpe Ratios of XERS and CTMX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

XERS vs. CTMX - Drawdown Comparison

The maximum XERS drawdown since its inception was -96.22%, roughly equal to the maximum CTMX drawdown of -98.74%. Use the drawdown chart below to compare losses from any high point for XERS and CTMX.

Drawdown Indicators

	XERS	CTMX	Difference
Max Drawdown Largest peak-to-trough decline	-96.22%	-98.74%	+2.52%
Max Drawdown (1Y) Largest decline over 1 year	-46.57%	-56.89%	+10.32%
Max Drawdown (3Y) Largest decline over 3 years	-49.83%	-91.59%	+41.76%
Max Drawdown (5Y) Largest decline over 5 years	-78.59%	-94.16%	+15.57%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.74%	—
Current Drawdown Current decline from peak	-73.56%	-90.79%	+17.23%
Average Drawdown Average peak-to-trough decline	-78.99%	-70.94%	-8.05%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.61%	24.26%	+2.35%

Volatility

XERS vs. CTMX - Volatility Comparison

The current volatility for Xeris Biopharma Holdings, Inc. (XERS) is 10.32%, while CytomX Therapeutics, Inc. (CTMX) has a volatility of 14.67%. This indicates that XERS experiences smaller price fluctuations and is considered to be less risky than CTMX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XERS	CTMX	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.32%	14.67%	-4.35%
Volatility (6M) Calculated over the trailing 6-month period	33.46%	67.16%	-33.70%
Volatility (1Y) Calculated over the trailing 1-year period	55.68%	93.70%	-38.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	68.45%	141.88%	-73.43%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.61%	111.37%	-31.76%

Dividends

XERS vs. CTMX - Dividend Comparison

Neither XERS nor CTMX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both XERS and CTMX in my portfolio?

XERS and CTMX have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, XERS or CTMX?

CTMX has higher volatility (14.67%) compared to XERS (10.32%). In terms of maximum drawdown, XERS dropped -96.22% vs CTMX's -98.74%.

Which has better risk-adjusted returns?

XERS currently has the higher Sharpe Ratio (1.00 vs 0.49), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.